SCHEMBL5534966

SCHEMBL5534966

COC(=O)Cc1cc(C)ccc1Nc1c(F)cccc1Cl

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 10/20 0.79
PTGS1 P23219 4/20 0.79
ABCB11 O95342 2/20 0.79
NR1I3 Q14994 2/20 0.79
PPARG P37231 1/20 0.79
CAMK2A Q9UQM7 1/20 0.48
TTR P02766 2/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
CYP2C9 P11712 1/20 0.45
TBXA2R P21731 1/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
AKR1B10 O60218 1/20 0.42
UGT1A9 O60656 1/20 0.42
TRPA1 O75762 1/20 0.42
MT-CO2 P00403 1/20 0.42
ALB P02768 1/20 0.42
CXCL8 P10145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lumiracoxib SCHEMBL29475008 0.88 PTGS2 (1.00) PTGS2PTGS1ABCB11NR1I3PPARG
Lumiracoxib SCHEMBL4479 0.88 PTGS2 (1.00) PTGS2PTGS1ABCB11NR1I3PPARG
SCHEMBL5533958 0.88 PTGS2 (0.82) PTGS2PTGS1ABCB11NR1I3PPARG
Lumiracoxib SCHEMBL29377334 0.88 PTGS2 (1.00) PTGS2PTGS1ABCB11NR1I3PPARG
SCHEMBL6036175 0.88 PTGS2 (0.78) PTGS2PTGS1ABCB11NR1I3PPARG
SCHEMBL13688515 0.87 PTGS2 (0.70) PTGS2PTGS1ABCB11NR1I3PPARG
Lumiracoxib SCHEMBL27680523 0.87 PTGS2 (0.98) PTGS2PTGS1ABCB11NR1I3PPARG
SCHEMBL17208147 0.86 PTGS2 (0.79) PTGS2PTGS1ABCB11NR1I3PPARG
SCHEMBL576935 0.85 PTGS2 (0.77) PTGS2PTGS1ABCB11NR1I3PPARG
SCHEMBL5155301 0.85 PTGS2 (0.66) PTGS2PTGS1ABCB11NR1I3PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541398-B2 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs ANTIBE THERAPEUTICS INC. (CA) 2013-09-24 US disclosed
US-8541398-B2 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs ANTIBE THERAPEUTICS INC. (CA) 2013-09-24 US disclosed
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES EMS S.A. (BR) 2012-05-10 US disclosed
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES EMS S.A. (BR) 2012-05-10 US disclosed
US-20100210607-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC. (CA) 2010-08-19 US disclosed
US-20100210607-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC. (CA) 2010-08-19 US disclosed
US-7741359-B2 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs ANTIBE THERAPEUTICS INC. (CA) 2010-06-22 US disclosed
US-7741359-B2 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs ANTIBE THERAPEUTICS INC. (CA) 2010-06-22 US disclosed
WO-2008009127-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-24 WO disclosed
US-20080004245-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-03 US disclosed
US-20080004245-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004245-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS PTGS1, HPGDS, PTGES PTGS2 4/4885PTGS1 1/4885ABCB11 1085/4885
US-20100210607-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS PTGS1, HPGDS, PTGES PTGS2 4/4885PTGS1 1/4885ABCB11 1085/4885
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES TNF, PER2, CRY1 PTGS2 12/4885PTGS1 8/4885ABCB11 3109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.